Amyris Inc  

(Public, NASDAQ:AMRS)   Watch this stock  
Find more results for AMRS
+0.018 (3.18%)
Real-time:   12:52PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.55 - 0.59
52 week 0.31 - 1.43
Open 0.55
Vol / Avg. 994,486.00/2.77M
Mkt cap 171.51M
P/E     -
Div/yield     -
EPS -0.39
Shares 278.32M
Beta 0.71
Inst. own 31%
May 23, 2017
Amyris Inc Annual Shareholders Meeting - 5:00PM EDT - Add to calendar
May 8, 2017
Q1 2017 Amyris Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 2, 2017
Q4 2016 Amyris Inc Earnings Call
Mar 2, 2017
Q4 2016 Amyris Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -219.24% -144.86%
Operating margin -169.80% -148.93%
EBITD margin - -114.92%
Return on average assets -170.57% -82.49%
Return on average equity - -
Employees 440 -
CDP Score - -


5885 Hollis St Ste 100
EMERYVILLE, CA 94608-2405
United States - Map
+1-510-4500761 (Phone)
+1-510-2252645 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

Officers and directors

John G. Melo President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Kathleen Valiasek Chief Financial Officer
Bio & Compensation  - Reuters
Joel Cherry Ph.D. President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Karen D. Rohde Chief Human Resources Officer
Bio & Compensation  - Reuters
Chris Jaenike Interim General Counsel
Bio & Compensation  - Reuters
Abraham Klaeijsen Director
Bio & Compensation  - Reuters
Christophe Vuillez Director
Bio & Compensation  - Reuters
Patrick Y. Yang Director
Bio & Compensation  - Reuters
Abdullah Bin Khalifa Al Thani Independent Director
Age: 55
Bio & Compensation  - Reuters
John L. Doerr Independent Director
Age: 63
Bio & Compensation  - Reuters